

Special Issue

Staphylococci Antimicrobial Tolerance, Persistent Infection and Antimicrobial Strategies

Message from the Guest Editors

Staphylococci are pathogens causing a vast array of infections. These organisms can infect virtually any tissue of the body. They were designated as a “persistent pathogen” due to their unusual recalcitrance towards antibiotic treatment, which to date has remained a major clinical challenge. Current antibiotics present a reduced capacity to eradicate staphylococci without surgical support. The application of “omics” technology to investigate staphylococcal physiological change mechanisms during infections helps us to understand the triggers of increased antibiotic survival. Due to a growing awareness of increased antibiotic survival, a great deal of research has turned its focus to new ways of treating and eradicating tolerant staphylococci. However, more studies are needed to better understand the dynamics, mechanisms and relevance of tolerant staphylococci at the site of infection. This Special Issue seeks manuscript submissions that further our understanding of advanced Staphylococci antimicrobial tolerance, persistent infection and antimicrobial strategies.

Guest Editors

Prof. Dr. Lei He

Prof. Dr. Xiancai Rao

Prof. Dr. Yan Chen

Deadline for manuscript submissions

closed (30 October 2023)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/144938

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)